157 related articles for article (PubMed ID: 8783669)
1. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.
List AF; Heaton R; Glinsmann-Gibson B; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):58-63. PubMed ID: 8783669
[TBL] [Abstract][Full Text] [Related]
2. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors.
List AF; Heaton R; Glinsmann-Gibson B; Capizzi RL
Leukemia; 1998 Oct; 12(10):1596-602. PubMed ID: 9766505
[TBL] [Abstract][Full Text] [Related]
3. Effects of amifostine on clonogenic mesenchymal progenitors and hematopoietic progenitors exposed to radiation.
Ramdas J; Warrier RP; Scher C; Larussa V
J Pediatr Hematol Oncol; 2003 Jan; 25(1):19-26. PubMed ID: 12544769
[TBL] [Abstract][Full Text] [Related]
4. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Taylor CW; Wang LM; List AF; Fernandes D; Paine-Murrieta GD; Johnson CS; Capizzi RL
Eur J Cancer; 1997 Sep; 33(10):1693-8. PubMed ID: 9389935
[TBL] [Abstract][Full Text] [Related]
5. Amifostine stimulates the formation of hematopoietic bone marrow progenitors from B-cell chronic lymphocytic leukemia.
Tsatalas C; Spanoudakis E; Pantelidou D; Margaritis D; Kotsianidis I; Chalkia P; Tripsianis G; Basdiara I; Kartasis Z; Karakolios A; Bourikas G
Acta Haematol; 2004; 112(3):136-40. PubMed ID: 15345895
[TBL] [Abstract][Full Text] [Related]
6. Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro.
Song H; Vita M; Sallam H; Tehranchi R; Nilsson C; Sidén A; Hassan Z
Cancer Chemother Pharmacol; 2007 Nov; 60(6):841-9. PubMed ID: 17318617
[TBL] [Abstract][Full Text] [Related]
7. In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
Pierelli L; Scambia G; Fattorossi A; Bonanno G; Battaglia A; Perillo A; Menichella G; Panici PB; Leone G; Mancuso S
Br J Cancer; 1998 Oct; 78(8):1024-9. PubMed ID: 9792145
[TBL] [Abstract][Full Text] [Related]
8. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
[TBL] [Abstract][Full Text] [Related]
9. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
Douay L; Hu C; Giarratana MC; Gorin NC
Eur J Cancer; 1995; 31A Suppl 1():S14-6. PubMed ID: 7577094
[TBL] [Abstract][Full Text] [Related]
10. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia.
List AF
Semin Oncol; 1999 Apr; 26(2 Suppl 7):61-5. PubMed ID: 10348262
[TBL] [Abstract][Full Text] [Related]
11. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
12. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of the antitumor effect of Merocyanine 540-mediated photodynamic therapy by amifostine and amphotericin B.
Tsujino I; Miyagi K; Sampson RW; Sieber F
Photochem Photobiol; 2006; 82(2):458-65. PubMed ID: 16613499
[TBL] [Abstract][Full Text] [Related]
14. Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells.
Broxmeyer HE; Cooper S; Lu L; Hangoc G; Anderson D; Cosman D; Lyman SD; Williams DE
Blood; 1991 May; 77(10):2142-9. PubMed ID: 1709371
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery.
Poloni A; Leoni P; Curzi L; Cantori I; Mancini S; Montanari M; Masia MC; Olivieri A
Exp Hematol; 1999 Oct; 27(10):1548-56. PubMed ID: 10517497
[TBL] [Abstract][Full Text] [Related]
16. Porcine brain microvascular endothelial cells support the in vitro expansion of human primitive hematopoietic bone marrow progenitor cells with a high replating potential: requirement for cell-to-cell interactions and colony-stimulating factors.
Davis TA; Robinson DH; Lee KP; Kessler SW
Blood; 1995 Apr; 85(7):1751-61. PubMed ID: 7535587
[TBL] [Abstract][Full Text] [Related]
17. Mast cell growth factor (c-kit ligand) supports the growth of human multipotential progenitor cells with a high replating potential.
Carow CE; Hangoc G; Cooper SH; Williams DE; Broxmeyer HE
Blood; 1991 Nov; 78(9):2216-21. PubMed ID: 1718490
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
Douay L; Hu C; Giarratana MC; Gorin NC
Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773
[TBL] [Abstract][Full Text] [Related]
19. Purging of small cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated merocyanine 540 phototreatment.
Meagher RC; Rothman SA; Paul P; Koberna P; Willmer C; Baucco PA
Cancer Res; 1989 Jul; 49(13):3637-41. PubMed ID: 2543500
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
